ProCE Banner Activity

Phase II Expansion Study of Ruxolitinib for the Treatment of Symptomatic CMML

Slideset Download
Conference Coverage

Emerging data with ruxolitinib show clinically meaningful activity and reductions in splenomegaly and disease-related symptoms in patients with CMML.

Released: December 13, 2022

Expiration: December 12, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen